The short answer
Chromium can affect glucose response during glipizide treatment, but evidence does not establish a new chromium requirement or a protective dosing interval. Supplement use warrants an individual glucose plan.
What this answer covers
Trivalent supplemental chromium, especially picolinate evidence; elemental dose and salt matter. Direct trial used glipizide GITS extended release.
- Supplement or preparation
- Chromium
- Medication ingredient
- glipizide
A trial included glipizide directly
Adults taking glipizide GITS received chromium picolinate or placebo. The chromium group showed improved insulin sensitivity and glucose control. This is direct combination evidence, but the inspected abstract does not provide a clinical hypoglycemia event rate.
Improved control is not the same as a low-glucose episode
The trial measured average control and insulin sensitivity. NIH guidance nevertheless cautions that chromium may add to glucose-lowering medicines, so people whose glucose is already near their target need an individual review.
No new nutritional need is established
These findings do not show that glipizide depletes chromium or that everyone should supplement. The trial tested one salt at a high supplemental amount, and its dose is not a recommendation for routine use.
Timing has not been shown to prevent the effect
Discuss the exact product and amount with the diabetes team before starting or changing it. Follow your established glucose-monitoring and low-glucose treatment plan; do not adjust glipizide yourself. Do not assume taking chromium several hours apart removes its effect on glucose regulation.
Evidence and practical considerations
Timing & monitoring
No changed chromium requirement or protective timing interval established; individualized monitoring is a narrower concern.
- Exact scope
- Trivalent supplemental chromium, especially picolinate evidence; elemental dose and salt matter. Direct trial used glipizide GITS extended release. with Oral glipizide RxCUI4821 IN, immediate and extended release distinguished.
- Medication form and route
- oral medication; oral supplement
What remains uncertain
- Exact source preparation, medication and endpoint limits apply; no universal dose change or spacing.
Factors that may matter: Formulation; Dose and duration; Meal pattern; Other glucose-lowering agents; Kidney and liver function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients with type 2 diabetes receiving glipizide.
Glipizide can cause severe hypoglycemia; added glucose-lowering agents warrant observation. Nicotinic acid can worsen glycemic control; withdrawal also needs observation.
How this applies: Exact glipizide formulation and supplement preparation matter; other sulfonylureas and glucose efficacy endpoints are not automatically glipizide hypoglycemia evidence.
Separate formulations and meal instructions; no automatic transfer of immediate-release antacid pharmacokinetics to XL. Does not establish a risk rate for these herbs.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients with type 2 diabetes receiving glipizide.
Glipizide can cause severe hypoglycemia; added glucose-lowering agents warrant observation. Nicotinic acid can worsen glycemic control; withdrawal also needs observation.
How this applies: Exact glipizide formulation and supplement preparation matter; other sulfonylureas and glucose efficacy endpoints are not automatically glipizide hypoglycemia evidence.
Separate formulations and meal instructions; no automatic transfer of immediate-release antacid pharmacokinetics to XL. Does not establish a risk rate for these herbs.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Adults with type 2 diabetes.
Chromium group had improved insulin sensitivity and glycemic control; the abstract does not provide a hypoglycemia event rate.
How this applies: Exact glipizide formulation and supplement preparation matter; other sulfonylureas and glucose efficacy endpoints are not automatically glipizide hypoglycemia evidence.
37initially evaluated; randomized groups described as17chromium and12placebo. One chromium salt and XL regimen, not a dose or timing requirement.
Source 4: federal health guidance
ods.od.nih.gov · Source check Sep 10, 2026
Population: Users of the specified supplement.
Chromium may add to glucose-lowering effects of diabetes medicines; clinical benefit is inconsistent. No established glipizide-induced requirement.
How this applies: Exact glipizide formulation and supplement preparation matter; other sulfonylureas and glucose efficacy endpoints are not automatically glipizide hypoglycemia evidence.
Not toxic industrial hexavalent chromium; guidance is not a quantified exact-pair trial.
Research assessment: · Open full citations ↗
Side effects & toxicity
Direct glipizide GITS chromium-picolinate trial supports changed glucose response, combined with federal additive-glucose precaution; no hypoglycemia rate established.
- Exact scope
- Trivalent supplemental chromium, especially picolinate evidence; elemental dose and salt matter. Direct trial used glipizide GITS extended release. with Oral glipizide RxCUI4821 IN, immediate and extended release distinguished.
- Medication form and route
- oral medication; oral supplement
What remains uncertain
- Exact source preparation, medication and endpoint limits apply; no universal dose change or spacing.
Factors that may matter: Formulation; Dose and duration; Meal pattern; Other glucose-lowering agents; Kidney and liver function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients with type 2 diabetes receiving glipizide.
Glipizide can cause severe hypoglycemia; added glucose-lowering agents warrant observation. Nicotinic acid can worsen glycemic control; withdrawal also needs observation.
How this applies: Exact glipizide formulation and supplement preparation matter; other sulfonylureas and glucose efficacy endpoints are not automatically glipizide hypoglycemia evidence.
Separate formulations and meal instructions; no automatic transfer of immediate-release antacid pharmacokinetics to XL. Does not establish a risk rate for these herbs.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients with type 2 diabetes receiving glipizide.
Glipizide can cause severe hypoglycemia; added glucose-lowering agents warrant observation. Nicotinic acid can worsen glycemic control; withdrawal also needs observation.
How this applies: Exact glipizide formulation and supplement preparation matter; other sulfonylureas and glucose efficacy endpoints are not automatically glipizide hypoglycemia evidence.
Separate formulations and meal instructions; no automatic transfer of immediate-release antacid pharmacokinetics to XL. Does not establish a risk rate for these herbs.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Adults with type 2 diabetes.
Chromium group had improved insulin sensitivity and glycemic control; the abstract does not provide a hypoglycemia event rate.
How this applies: Exact glipizide formulation and supplement preparation matter; other sulfonylureas and glucose efficacy endpoints are not automatically glipizide hypoglycemia evidence.
37initially evaluated; randomized groups described as17chromium and12placebo. One chromium salt and XL regimen, not a dose or timing requirement.
Source 4: federal health guidance
ods.od.nih.gov · Source check Sep 10, 2026
Population: Users of the specified supplement.
Chromium may add to glucose-lowering effects of diabetes medicines; clinical benefit is inconsistent. No established glipizide-induced requirement.
How this applies: Exact glipizide formulation and supplement preparation matter; other sulfonylureas and glucose efficacy endpoints are not automatically glipizide hypoglycemia evidence.
Not toxic industrial hexavalent chromium; guidance is not a quantified exact-pair trial.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact glipizide article preserving formulation, preparation and glucose endpoint distinctions. | |
| Research summary published |
Article revision: 63ed56c4b2c4095b
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.